Physiopathology of urticaria

European Journal of Dermatology

Volumn 9, Issue 8, 1999, Pages 601-605

  Doutre, Marie Sylvie ^a  

^a Hôp Haut Lévêque ^*  (France)

Author keywords

IgE receptors; Immediate allergy; Late phase response; Mast cells; Urticaria

Indexed keywords

FC RECEPTOR; HISTAMINE H1 RECEPTOR; ICOSANOID; IMMUNOGLOBULIN E RECEPTOR; KININ; NEUROPEPTIDE; SEROTONIN;

CYTOKINE PRODUCTION; ENDOTHELIUM CELL; HISTAMINE RELEASE; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOPATHOLOGY; IMMUNOREGULATION; PATHOPHYSIOLOGY; REVIEW; URTICARIA;

BASOPHILS; HUMANS; HYPERSENSITIVITY, IMMEDIATE; MAST CELLS; URTICARIA;

EID: 0033458048     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. 1. Greaves MW. Chronic urticaria. N Engl J Med 1995; 332: 1762-72.
2. 2. Barlow RJ, Ross EL, Mac Donald DM, Kobza Black A, Greaves MW. Mast cells and T lymphocytes in chronic urticaria. Clin Exp Allergy 1995; 25: 317-22.
3. 3. Elias J, Boss E, Kaplan AP. Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocytes, monocytes and mast cells. J Allergy Clin Immunol 1986; 78: 914-8.
4. 4. Smith CH, Kepley C, Schwartz L, Lee TH. Mast cell number and phenotype in chronic idiopathic urticaria. J Allergy Clin Immunol 1995; 96: 360-4.
5. 5. Mehregan DR, Gibson LE. Pathophysiology of urticarial vasculitis. Arch Dermatol 1998; 134: 88-9.
6. 6. Claveau J, Lavoie A, Brunet C, Bedard PM, Hebert J. Chronic idiopathic urticaria: possible contribution of histamine releasing factor to pathogenesis. J Allergy Clin Immunol 1993; 92: 132-7.
7. 7. Church MK, Lowman MA, Robinson C, Holgate ST, Benyon RC. Interaction of neuropeptides with human mast cells. Int Arch Allergy Appl Immunol 1989; 88: 70-8.
8. 8. Smith CH, Atkinson B, Morris RW, Hayes N, Foreman JC, Lee TH. Cutaneous responses to vasoactive intestinal polypetide in chronic idiopathic urticaria. Lancet 1992; 339: 91-3.
9. 9. Misery L, Schmitt D, Claudy A. Les neuromédiateurs et la peau. Perspectives pour les dermatoses allergiques? Rev Fr Allergol 1997; 37: 549-55.
10. 10. Galli SJ. New concepts about the mast cell. N Engl J Med 1993; 328: 257-65.
11. 11. Schwartz LB. Mast cells and their role in urticaria. J Am Acad Dermatol 1991; 25: 190-204.
12. 12. Rosentreich DL. Chronic urticaria, activated T cells and mast cell releasibility. J Allergy Clin Immunol 1986; 78: 1099-102.
13. 13. Prin L. Mastocytes, basophiles, éosinophiles. Analyse des marqueurs biologiques. Rev Fr Allergol 1996; 36: 889-96.
14. 14. Haas N, Iwen W, Grabbe J, Hamann K, Czarnetzki BM. β2 integrins in different forms of urticaria. Br J Dermatol 1995; 133: 48-53.
15. 15. Triggiani M, Casolaro V, Genovese A, Spadaro G, Marone G. Heterogeneity of human FcεRI beaning cells. Ann Allergy 1993; 71: 133-8.
16. 16. Sabroe RA, Greaves MW. The pathogenesis or chronic idiopathic urticaria. Arch Dermatol 1997; 133: 1003-8.
17. 17. Benhamou M. Antigènes de différenciation des mastocytes, basophiles et éosinophiles: mécanismes d'activation. Rev Fr Allergol 1996; 36: 879-83.
18. 18. Matis WL, Lauker RM, Murphy GF. Substance P induces the expression of an ELAM by microvascular endothelium. J Invest Dermatol 1990; 94: 492-5.
19. 19. Benyon RC, Robinson C, Church MK. Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependant and non immunological stimuli. Br J Pharmacol 1989; 97: 899-904.
20. 20. Nguyen KL, Gillis S, Mac Glashan DW. A comparative study of releasing and non-releasing human basophils, non releasing basophils lack an early component of the signal transduction pathway that follows IgE cross linking. J Allergy Clin Immunol 1990; 85: 1020-9.
21. 21. Mac Glashan DW. Releasibility of human basophils: cellular sensitivity and maximal histamine release are independant variables. J Allergy Clin Immunol 1993; 91: 605-15.
22. 22. Lawlor F, Bird C, Camp RDR, Barlow R, Barr RM, Kobza Black A, Judge MR, Greaves MW. Increased interleukin-6, but reduced interleukin-1 in delayed pressure urticaria. Br J Dermatol 1993; 128: 500-3.
23. 23. Schroeder JT, Kagey-Sobotka A, Lichtenstein LM. The role of the basophil in allergic inflammation. Allergy 1995; 50: 463-72.
24. 24. Frew AJ, Kay AB. Eosinophils and T-lymphocytes in late-phase allergic reactions. J Allergy Clin Immunol 1990; 85: 533-9.
25. 25. Capron M, Gruart V, Prin L, Tonnel AB. L'éosinophile: récepteurs et médiateurs. Rev Fr Allergol 1990; 30: 71-5.
26. 26. Wershil BK, Wang ZS, Gordon JR, Galli SJ. Recruitment of neutrophils during IgE-dependant cutaneous late phase reactions in the mouse is mast cell dependant. J Clin Invest 1991; 87: 446-53.
27. 27. Zweiman B, Atkins PC, Von Allmen C. Release of eosinophil granule proteins during IgE mediated reactions. J Allergy Clin Immunol 1991; 87: 984-92.
28. 28. McEvoy MT, Peterson EA, Kobza-Black A, English JSC, Dover JS, Murphy GM, Bhogal B, Greaves MW, Winkelmann RK, Leiferman KM. Immunohistological comparison of granulated cell proteins in induced immediate urticarial dermographism and delayed pressure urticaria lesions. Br J Dermatol 1995; 133: 853-60.
29. 29. Okayama Y, Bradding P, Tunon De Lara M, Holgate ST, Church MK. Cytokine production by human mast cells. Human basophils and mast cells: biological aspects. Marone ed. Chem Immunol Basel Karger 1995; 61: 114-34.
30. 30. Walsh U, Trinchieri G, Waldort HA, Whitaker D, Murphy G.F. Human dermal mast cells contain and release tumor necrosis factor α, which induces endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci USA 1991; 88: 422-4.
31. 31. Tillie-Leblond I, Gosset P, Janin A, Dalenne R, Joseph M, Wallaert B, Tonnel AB. Tumor necrosis factor α release during systemic reaction in cold urticaria. J Allergy Clin Immunol 1994; 93: 501-9.
32. 32. Hamawy MM, Mergenhagen SE, Siraganian RP. Adhesion molecules as regulators of mast-cells and basophil function. Immunol Today 1994; 15: 62-6.
33. 33. Kuna P, Reddigari ST, Schall TJ, Rucinski D, Viksman MY, Kaplan AP. RANTES, a monocyte and T lymphocyte chemotactic cytokine releases histamine from human basophils. J Immunol 1992; 146: 636-42.
34. 34. Zavadak D, Tharp MD. Chronic urticaria as a manifestation of the late phase reaction. Immunol Allergy Clin N Am 1995; 15: 745-59.
35. 35. Ying S, Meng Q, Taborda-Barata L, Kay AB. Association of apoptosis of neutrophils and eosinophils and their ingestion by macrophages with resolution of the allergen-induced cutaneous late-phase response in atopic human subjects. Proc Ass Am Phys 1997; 109: 42-50.
36. 36. Barlow RJ, Ross EL, Mac Donald D, Kobza-Black A, Greaves MW. Adhesion molecule expression and the inflammatory cell infiltrate in delayed pressure urticaria. Br J Dermatol 1994; 131: 341-7.
37. 37. Hide M, Francis DM, Grattan CEH, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993; 328: 1599-604.
38. 38. Fiebiger E, Maurer D, Holub H, Reininger B, Hartmann G, Woisetschlager M, Kinet JP, Stingl G. Serum IgG autoantibodies directed against the α chain of FcεRI: a selective marker and pathogenic factor for a distinct subset of chronic urticaria patients? J Clin Inv 1995; 96: 2606-12.
39. 39. Ferrer M, Kinet JP, Kaplan AP. Comparative studies of functional and binding assays for IgG anti-FcεRIα (α subunit) in chronic urticaria. J Allergy Clin Immunol 1998; 101: 672-6.
40. 40. Niimi N, Francis FF, Kermani F, O'Donnel BF, Hide M, Kobza-Black A, Winkelmann RK, Greaves MW, Barr RM. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol 1996; 106: 1001-6.
41. 41. Fiebeger E, Hammer Schmid F, Stingl G, Maurer D. Anti-FcεRIα autoantibodies in autoimmune mediated disorders. Identification of a structure-function relationship. J Clin Inv 1998; 101: 243-51.
42. 42. Tong LJ, Balakrishnan G, Kochan JP, Kinet JP, Kaplan AP. Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol 1997; 99: 461-5.
43. 43. Hide M, Francis DM, Grattan CEH, Barr RM, Winkelmann RK, Greaves MW. The pathogenesis of chronic idiopathic urticaria: new evidence suggests an auto-immune basis and implications for treatment. Clin Exp Allergy 1994; 24: 624-7.
44. 44. Heymann WR. Chronic urticaria and angio oedema associated with thyroid auto-immunity: review and therapeutic implications. J Am Acad Dermotol 1999; 40: 229-32.
45. 45. Gruber BL, Baeza ML, Marchese MJ, Agnello V, Kaplan AP. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988; 90: 213-7.
46. 46. Zweiman B, Valenzano M, Atkins PC, Tanus T, Getsy JA. Characteristics of histamine releasing activity in the sera of patients with chronic idiopathic urticaria. J Allergy Clin Immunol 1996; 98: 89-98.
47. 47. Kermani F, Niimi N, Francis DM, O'Donnell B, Black AK, Hafizi S, Yacoub M, Greaves MW, Barr RM. Characterization of a novel mast cell specific histamine releasing activity in chronic idiopathic urticaria. J Invest Dermatol 1995; 105: 452.
48. 48. Tharp MD. Chronic urticaria: pathophysiology and treatment approaches. J Allergy Clin Immunol 1996; 98: S325-30.
49. 49. Greaves MW. Urticaria: causes and treatment. Rev Fr Allergol 1998; 38: 935-7.
50. 50. Grattan CEH, Francis DM, Slater NGR, Barlow RJ, Greaves MW. Plasmapheresis for severe, unremitting, chronic urticaria. Lancet 1992; 339: 1078-80.
51. 51. Barlow RJ, Kobza-Black A, Greaves MW. Treatment of severe chronic urticaria with cyclosporin A. Eur J Dermatol 1993; 3: 273-5.
52. 52. O'Donnell BF, Barr RM, Kobza Black A, Francis DM, Kermani F, Niimi N, Barlow RJ, Winkelmann RK, Greaves MW. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 1998; 138: 101-6.
53. 53. Sabroe RA, Francis DM, Barr RM, Kobza Black A, Greaves MW. Anti-FcεRI autoantibodies and basophil histamine releasibility in chronic idiopathic urticaria. J Allergy Clin Immunol 1998; 102: 651-8.